(Received for publication November 8, 1985) In the course of our anticancer drug discovery program, the fermentation broth of an unidentified actinomycete isolate (WP 3688) was found to exhibit in vitro activity against L1210 lym- (2)2), including the expected bathochromic shift in base. High resolution mass spectrometry established C19H14O6 as the molecular formula of PD 116,779 which differs from that of tetrangomycin by the presence of one additional oxygen atom. Strong absorptions in the IR spectrum at 1637, 1669, and 1702 cm-1 could be assigned to chelated and nonchelated quinone carbonyls and the expected C(1) ketone functionality, respectively, and provided additional evidence for the presence of the benz[a]anthraquinone nucleus.
The downfield region of the 1H NMR spectrum of PD 116,779 exhibits a signal for a phenolic proton at 12.07 ppm as well as overlapping sets of aromatic signals belonging to an ABX and an AB system, consistent with the aromatic nucleus of 2. The remaining 1H NMR signals correspond to a pair of nonequivalent methylene protons, a tertiary methyl group, and > CHOH, as well as secondary and tertiary hydroxyl functionalities. Together with the data described above, these protons could be assigned to the A ring of the benz[a]anthraquinone skeleton. The lack of coupling between the > CHOH and CH, protons suggests that the tertiary methyl and hydroxyl groups are both attached to the C(3) position, as in tetrango- 1986 mycin.
The secondary hydroxyl functionality, therefore, must occupy one of the remaining C(2) or C(4) positions. The placement of the hydroxyl at C(2) was determined by analysis of the 1H NMR homonuclear correlation spectrum (COSY), which clearly showed a correlation between one of the two aromatic protons (H(5)) in the AB system described above with both of the methylene protons, which necessarily must be placed on C(4). On the basis of these data, PD 116,779 can confidently be assigned structure 
